# Sanavia Oncology Inc.

> Sanavia Oncology is a New York-based biotech company developing next-generation cancer immunotherapies for patients who don't benefit from existing treatments. Its proprietary platform pairs high-throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling and artificial intelligence to discover novel, clinically relevant cancer-specific epitopes in drug-resistant tumors, then generates antibodies with atomic-level specificity to those targets. The company is building antibody drug conjugates (ADCs), bispecific T cell engagers (TCEs) and CAR-T therapies - led by its SANA-01 ADC - and is backed by Two Bear Capital.

- **Headquarters:** New York, New York, United States
- **Founders:** Server Ertem (Founder & Chief Executive Officer)
- **Team size:** Approximately 14 employees
- **Products:** Epitope Discovery Platform, SANA-01 ADC, Bispecific T Cell Engagers (TCE), CAR-T Cell Therapies
- **Notable:** Built a proprietary multi-modal discovery platform integrating high-throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling and AI., Advanced lead ADC SANA-01 against an epitope shared across a majority of patients in several major solid tumors., Raised approximately $26M in venture funding led by Two Bear Capital.

## Products & services

- **Epitope Discovery Platform** — Proprietary platform that discovers unexplored, clinically relevant, cancer-specific epitopes in drug-resistant tumors by combining high-throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling, artificial intelligence and novel in vivo models for target validation.
- **SANA-01 ADC** — Lead antibody drug conjugate targeting a novel, cancer-specific epitope present in a high percentage of patients across major cancers, including up to 75% of lung, 70% of TNBC, 70% of ovarian, 40% of colon, 75% of pancreatic and 55% of gastric cancers.
- **Bispecific T Cell Engagers (TCE)** — Bispecific antibody therapies that redirect T cells against novel, stable, first-in-class epitopes in validated cancer targets.
- **CAR-T Cell Therapies** — Engineered CAR-T programs aimed at the same class of novel cancer-specific epitopes identified by the discovery platform.

## Achievements

- Built a proprietary multi-modal discovery platform integrating high-throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling and AI.
- Advanced lead ADC SANA-01 against an epitope shared across a majority of patients in several major solid tumors.
- Raised approximately $26M in venture funding led by Two Bear Capital.
- Recruited a team drawn from Rockefeller, MSK, Columbia, Weill Cornell and top pharma.
- Selected to exhibit/present at the BIO International Convention (2025 and 2026).

## Latest updates

- **2026-01** — Listed among presenters/exhibitors for the BIO International Convention 2026.
- **2025-06** — Featured at the BIO International Convention 2025 as an emerging oncology company.
- **2023-07** — Reported venture funding round; total funding reported around $26M with backing from Two Bear Capital.

## Links

- Website: https://sanavia.bio
- LinkedIn: https://www.linkedin.com/company/sanavia-oncology
- YouTube: https://www.youtube.com/@sanavia_oncology

---

Profile page: https://yespress.io/sanavia-oncology-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-18